Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow Print PDF (237K) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Gu, X
Right arrow Articles by Marzluff, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gu, X
Right arrow Articles by Marzluff, W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 Oxford University Press 3797-3805

Footnote

3 ' Processing and termination of mouse histone transcripts synthesized in vitro by RNA polymerase II

3 ' Processing and termination of mouse histone transcripts synthesized in vitro by RNA polymerase II Xiaohong Gu and William F. Marzluff*

Program in Molecular Biology and Biotechnology, Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill , NC 27599, USA

Received May 29, 1996; Revised and Accepted August 18, 1996

ABSTRACT

The highly expressed mouse histone H2a-614 gene is located 800 nt 5 ' of the histone H3-614 gene. There is a 140 nt sequence located 500 nt from the end of the H2-614 mRNA which has been defined as a transcription termination site for RNA polymerase II. We established an in vitro transcription system in which both 3 ' end processing and transcription termination occur. A template containing the adenovirus major late promoter, a portion of the histone H2a-614 coding region, its 3 ' processing signal, followed by the transcription termination site was transcribed in a nuclear extract prepared from mouse myeloma cells. Some of the transcripts synthesized in the extract were cleaved at the histone processing site in a reaction which was dependent both on the hairpin binding factor and the U7 snRNP. The efficiency of histone 3 ' end formation was similar both on synthetic transcripts and transcripts synthesized by RNA polymerase II. Defined transcripts, which were not processed and which mapped to the transcription termination site, were released from the template, suggesting that they were formed by transcription termination. Termination in vitro was dependent on a functional histone processing signal.

INTRODUCTION

The final step in transcription of RNA from the DNA template is termination of transcription and release of both the nascent RNA product and RNA polymerase from the template. Efficient transcription termination is important for recycling RNA polymerase molecules and preventing transcription interference from the upstream run-on transcription. Recent studies have shown that transcription termination is tightly coupled to 3' end processing (reviewed in ref. 1 ). To understand the molecular basis of transcription termination, it is necessary to have a system in which the various events of RNA metabolism all occur, starting with transcription from a DNA template. As a start in this direction, we have established an in vitro system capable of both 3' end formation and transcription termination from the mouse histone H2a-614 gene.

The mechanism of termination by RNA polymerase II (pol II) is not well understood. RNA polymerase II transcribes three classes of genes: (i) genes encoding the polyadenylated mRNAs, (ii) the replication-dependent histone genes and (iii) the capped small nuclear RNA genes. The 3' end of polyadenylated RNAs is formed by cleavage of the nascent transcript and transcription continues past the cleavage site. Transcription termination on genes encoding polyadenylated mRNAs is dependent on the presence of a functional polyadenylation site ( 2 - 6 ). In cases where there are two genes which are close together, transcription must terminate between the two genes to prevent disruption of the transcription complex on the downstream promoter by a polymerase transcribing the upstream gene. In several cases where there are two closely positioned genes, transcription termination sites have been identified ( 7 , 8 ). For some genes protein factors which bind the sequence required for transcription termination have been identified ( 9 - 12 ). In cases where genes are relatively far apart, transcription does not terminate precisely but rather ends in a broad region 3' of the polyadenylation site ( 13 , 14 ). The prevailing model is that a polyadenylation site and a transcription pause site(s) combine to form a complete termination site ( 15 , 16 ). Thus cleavage at the polyadenylation site, followed by degradation of the free 5' end of the nascent RNA by a 5' -> 3' nuclease, is a critical step in transcription termination ( 1 ).

Histone mRNAs are the only mRNAs which do not end in a polyA tail ( 17 ). The 3' end processing signal contains a 16 nt stem-loop followed by a purine-rich U7 snRNP binding site ( 18 - 21 ). The 3' end of histone mRNAs is formed by a cleavage reaction between the stem-loop and the purine-rich sequence ( 22 ), with transcription continuing for at least a few hundred nt past the 3' end of the mRNA ( 23 , 24 ). As in polyadenylated mRNAs, termination of transcription requires a functional histone 3' processing signal ( 24 ). The 3' end processing reaction requires a U7 snRNP binding to a purine-rich sequence and a stem-loop binding protein (SLBP) which recognizes the stem-loop ( 20 , 25 , 26 ).

In one histone gene, the mouse histone H2a-614 gene which is only 800 nt upstream of the H3-614 gene, a transcription termination site has been identified ( 24 ). This termination region is 140 nt long, GC-rich (75%), and located 550 nt downstream of the processing site of the H2a-614 gene. For this gene `terminated' H2a-614 pre-mRNAs were detected in cells suggesting that cleavage of the nascent transcript is not a prerequisite for transcription termination ( 24 ). Here, we report conditions that allow both transcription and processing of a transcript from a template that contains both a mouse histone H2a-614 3' processing signal and transcription termination site. In addition to the processed transcripts, we also detected and mapped full-length transcripts which terminated at the termination site as judged by their release from the supercoiled template.

MATERIALS AND METHODS

Preparation of nuclear extract

Mouse myeloma cells were grown in suspension culture in Dulbecco's Modified Eagle's Medium plus 10% horse serum and harvested at a concentration of 4-6 * 10 5 cells/ml. Nuclei were prepared essentially by the method of Shapiro et al . ( 27 ), as previously described ( 28 ). The nuclei were extracted with varying salt concentrations ranging from 0.22 M KCl, optimal for histone 3' processing, to 0.35-0.6 M KCl, optimal for in vitro transcription. For low salt extracts, where the nuclei did not break and the chromatin did not swell, the nuclei were removed by centrifugation at 20 000 g for 30 min. For high salt extracts, the chromatin was removed by centrifugation at 100 000 g for 1 h. The resulting supernatant was dialyzed against 20 mM HEPES, pH 7.9, 20% glycerol, 100 mM KCl, 0.2 mM EDTA and 0.5 mM DTT. Precipitated material was removed by centrifugation, and the supernatant was stored at -80oC in small aliquots. Typical protein concentrations were 4-6 mg/ml.

Transcription in nuclear extracts

The HLST gene contains the adenovirus major late promoter (MLP) fused to a portion of the mouse histone H2a-614 gene containing the 3' processing signal, followed by the transcription termination region (Fig. 2 A). The genes HLT, HLST M1 and HLST M2 were constructed from the HLST gene by substituting the appropriate terminator mutations (HLST M1 and HLST M2 genes) or by deleting the 92 nt starting at the Sac I site in the 3' UTR and extending site past the U7 snRNP binding site (HLT gene; Fig. 2 A). Either supercoiled or linear templates cleaved 382 nt from the MLP start site were used. Transcription was carried out in a 20 [mu]l reaction containing 1 [mu]g template DNA, 15 [mu]l (75 [mu]g protein) nuclear extract, 7.5 mM MgCl 2 , 1 mM ATP, CTP, GTP, 10 [mu]M UTP and 10 [mu]Ci [[alpha]- 32 P]UTP (3000 Ci/mmol) and 30 [mu]g yeast tRNA at 25oC. After addition of 1% SDS and 10 mM EDTA to stop the reaction, RNA was prepared by extraction with phenol and recovered by precipitation with ethanol. The RNA products were resolved by electrophoresis on 6% polyacrylamide-7 M urea gels and detected by autoradiography and quantified on a PhosphorImager (Molecular Dynamics).

To map the transcripts antisense oligonucleotides (1 [mu]g) were included in the reaction. These oligonucleotides result in cleavage of the transcripts at specific sites by the endogenous RNase H in the extract ( 29 ).

Histone pre-mRNA processing

A 322 nt substrate containing a portion of the H2a-614 coding region, the 3' end and processing signal and 60 nt of flanking sequence was synthesized using T7 RNA polymerase as previously described ( 28 ). Reactions were carried out in a final volume of 20 [mu]l containing 17 [mu]l nuclear extract (85 [mu]g protein), 10 000 c.p.m. pre-mRNA transcript (3 * 10 4 c.p.m./[mu]g; 0.33 pmol) and 20 mM EDTA. The reactions were incubated at 32oC for 30 min and were stopped by the addition of NaOAc and extracted with phenol. The RNA was recovered by ethanol precipitation and analyzed on a 6% polyacrylamide-7 M urea gel. The RNA was detected by autoradiography and quantified using a PhosphorImager (Molecular Dynamics).

Assay for transcript release

To determine whether the transcript was released from the template, the reaction was adjusted to 0.5 M NaCl and applied to a 1.5 ml (0.6 * 30 cm) Agarose A15M (BioRad) column equilibrated with 0.5 M NaCl, 10 mM HEPES, pH 7.2, 0.1 mM EDTA in a 2 ml disposable pipette. Five drop fractions were collected. RNA was prepared from each fraction by extraction with phenol-chloroform, recovered by ethanol precipitation, and resolved by electrophoresis on a 6% polyacrylamide-7 M urea gel.

RESULTS

The synthesis of histone mRNA is a much simpler process than the synthesis of most mRNAs. Once the transcript has been initiated, there are only two additional steps: cleavage of the nascent transcript to produce the mature mRNA and termination of the RNA transcript releasing the RNA polymerase. Conditions for efficient processing of synthetic histone pre-mRNAs have been developed ( 21 , 30 ). However, the reaction proceeds in vitro optimally in the absence of Mg 2+ , conditions incompatible with transcription. We sought to develop conditions which were compatible with both transcription by RNA polymerase II and histone 3' end formation.

A system which can both transcribe and process histone pre-mRNA

Previously we developed an efficient in vitro processing system from mouse myeloma cell nuclei by extracting the nuclei with 0.22 M KCl. Higher concentrations of KCl resulted in extracts with diminished processing activity ( 28 ). The extracts prepared at 0.22 M KCl were not active in transcription (data not shown). However, extraction of nuclei at a higher salt concentration, 0.35-0.6 M KCl, resulted in extracts that were active in transcription by RNA polymerase II, and were less active in histone pre-mRNA processing.

We tested the various extracts for the ability to cleave histone pre-mRNAs, and also tested to see whether conditions compatible with transcription and the cleavage reaction could be obtained. The histone processing reaction occurred efficiently in the low salt extract in the absence of Mg 2+ (Fig. 1 A, lane 2), but there was only a small amount of processing in a high salt extract (Fig. 1 A, lane 1) using the same conditions. To improve the processing efficiency without reducing the transcription activity, we mixed the processing extract and the transcription extract. The optimal ratio which allowed both processing and transcription at reasonable rates was a 1:3 ratio of processing extract to transcription extract. When the two extracts were mixed, there was an intermediate processing activity in the absence of divalent cations (Fig. 1 A, lane 3). However, when the reaction was carried out in the presence of Mg 2+ (Fig. 1 A, lane 4) or in the presence of Mg 2+ and ribonucleotide triphosphates (Fig. 1 A, lane 5), there was very little accumulation of the processed mRNA. Chelation of the Mg 2+ by adding EDTA restored the processing activity (Fig. 1 A, lane 6). Thus, under normal conditions for in vitro transcription the histone pre-mRNA cleavage reaction was very inefficient.


Figure 1 . Processing of histone pre-mRNA in vitro . ( A ) A radiolabeled 322 nt histone pre-mRNA was incubated with a mouse myeloma nuclear extract prepared with 0.4 (lane 1) or 0.22 M KCl (lane 2). The transcription and processing extracts were mixed (3:1) and the precursor RNA incubated in the presence of 20 mM EDTA (lane 3), 5 mM Mg 2+ (lane 4), 0.5 mM of the four ribotriphosphates plus Mg 2+ (lane 5), or in the presence of NTPs, Mg 2+ and 20 mM EDTA (lane 6). The RNA was purified and analyzed by electrophoresis on a 6% polyacrylamide-7 M urea gel. The position of the pre-mRNA and processed mRNA is indicated. ( B ) The transcription and processing extracts were mixed in a 3:1 ratio and incubated with the radiolabeled pre-mRNA. Yeast tRNA (30 [mu]g) was added to the reactions in lanes 2, 4 and 6. The reactions included 20 mM EDTA (lanes 1 and 2), 5 mM Mg 2+ (lanes 3 and 4), or 0.5 mM of the four ribotriphosphates plus 5 mM Mg 2+ (lanes 5 and 6). The position of the mRNA is indicated (SL) and the smaller product observed in the presence of Mg 2+ is designated SL -5 . ( C ) The transcription and processing extracts were mixed and incubated with the radiolabeled pre-mRNA. An antisense oligonucleotide to the 5' end of U7 snRNA was included in the reactions in lanes 2, 4, 6 and 8. The reactions in lanes 1-4 were incubated in 20 mM EDTA, and the reactions in lanes 5-8 were incubated with 5 mM Mg 2+ , and 0.5 mM of each of the four ribotriphosphates. Yeast tRNA (30 mg) was added to reactions in lanes 3, 4, 7 and 8. The RNAs are labeled as in (B). A diagram of the precursor and product mRNAs is shown below the figure.


Figure 2 . Transcription and processing from the HLST construct. ( A ) The HLST construct is shown. It contains the adenovirus major late promoter (Ad-MLP), a portion of the adenovirus sequence fused to the 3' end of the histone H2a-614 gene including the 3' processing signal; followed by the histone H2a-614 processing signal and transcription termination site. The terminator region extends from 209 to 355 nt from the transcription start site. The distances to the processing site, the termination site and the Hin dIII site used to produce run-off transcripts in some experiments is shown. The sequence of the terminator region is shown below the diagram. The position of the oligonucleotides used to map the in vitro transcripts is shown. The asterisks indicate the termination site mapped in vivo (24). Three other genes, the HLT gene which has a 92 nt deletion removing the stem-loop and the U7 site, the HLST M1 gene which has a deletion of the 3' end of the terminator region which does not affect termination in vivo , and the HLST M2 gene which has a 9 nt mutation in the terminator which abolished termination in vivo , were also constructed. The 9 nt change in the HLST M1 gene is shown and the position of the deletion in the HLST M2 gene is indicated by the upward arrow. ( B ) The plasmid containing the HLST construct was linearized at the Hin dIII site and incubated in a transcription extract (lane 2), or with a 3:1 mixture of a transcription and processing extract (lanes 3 and 5-7). In lane 6, 1 [mu]g of a competitor 30 nt RNA containing the stem-loop sequence was added, and in lane 7, 1 [mu]g of a competitor 30 nt RNA containing the stem-loop with the sequence of the stem reversed was added. The position of the SL -5 product formed in the presence of Mg 2+ , as well as the expected position of termination products (T) and run-off transcripts (RO) are indicated. Lanes 1 and 4 are marker DNAs, pUC18 digested with Hpa II. ( C ) To map the SL -5 transcripts, the supercoiled HLST construct was incubated with a 3:1 mixture of transcription and processing extract in the presence of oligonucleotides A (lane 1), A + B (lane 2), A + C (lane 3) and A + D (lane 4). The position of the antisense oligonucleotides are indicated below the figure. The position of marker DNA fragments are indicated. ( D ) The HLST construct linearized at a site 680 nt from the start of transcription was incubated with a mixture of a transcription and processing extract for 10 (lane 2), 30 (lane 3) or 60 min (lane 4). The HLST construct used in this experiment had an additional 300 nt inserted between the histone 3' end and the termination site and hence the terminated RNAs and the run-off RNAs were not resolved well from each other. The RNA products were analyzed by gel electrophoresis. The position of the initial processed product (SL) and the product ultimately formed in the presence of Mg 2+ (SL -5 ) is indicated. RO is the run-off transcription product. Lane 1 is pUC18 digested with Hpa II.

A possible explanation for the lower activity of the high salt extract is the presence of proteins that could non-specifically bind the RNA substrate and inhibit processing. The inhibitory effect of Mg 2+ could be due to the activation of nucleases which degrade the product. A Mg 2+ dependent 3' -> 5' exonuclease present in mammalian polyribosomes has been described ( 31 - 33 ) as well as a distinct 3' -> 5' exonuclease present in HeLa nuclear extracts ( 34 ). Since it seemed possible that the cleavage product might be rapidly degraded in the presence of Mg 2+ by nucleases in the extract, we added an excess of yeast tRNA as a competitor both for nucleases and for non-specific RNA binding proteins. Addition of tRNA to the processing reaction increased the processing activity even in the absence of divalent cations (Fig. 1 B, lanes 1 and 2). Addition of tRNA also restored activity in the reactions incubated out in the presence of Mg 2+ or Mg 2+ plus nucleotide triphosphates (Fig. 1 B, lanes 3, 4, 5 and 6). The processed mRNA formed in the presence of EDTA is formed by cleavage after the CA 5 nt from the end of the stem-loop (Fig. 1 B, lanes 1 and 2; band SL) . The product which accumulates in the presence of Mg 2+ is 5 nt shorter, ending at the base of the stem (Fig. 1 B, lanes 3-6; band SL -5 ; see Fig. 2 C). The shorter product is probably formed by a Mg 2+ dependent nuclease activity which trims the end of the histone mRNA, stopping at the base of the stem.

Formation of the SL -5 product in the presence of Mg 2+ could result either from processing followed by trimming of the processed transcript, or from exonucleolytic cleavage of the substrate. To show that some of the SL -5 product resulted from histone pre-mRNA processing, we inhibited processing by inactivating U7 snRNP. Histone 3' end formation is absolutely dependent on U7 snRNP and can be completely inhibited by antisense oligonucleotides directed against the 5' end of U7 snRNA ( 35 , 36 ). When we added U7 antisense oligonucleotides to the processing reactions, the formation of histone 3' ends observed in the presence of EDTA was completely inhibited (Fig. 1 C, lanes 2 and 4). However, the formation of the `processed' histone transcripts observed in the presence of Mg 2+ was only partially inhibited (50-70%) by the same oligonucleotide (Fig. 1 C, lanes 5 and 6), suggesting that some of these RNAs were formed by a nucleolytic cleavage which did not depend on U7 snRNP. While the addition of tRNA again increased the amount of product formed, again only 70% of the SL -5 product was sensitive to the antisense U7 oligonucleotide (Fig. 1 C, lanes 7 and 8), Thus in the presence of Mg 2+ there is an active nuclease(s) which can degrade the pre-mRNA or processed mRNA stopping at the base of the stem. However, ~70% of the SL -5 product is formed by a U7 snRNP-dependent reaction. Thus by mixing optimal processing and transcription extracts and by adding excess tRNA, we were able to produce an extract which was capable of carrying out histone 3' end formation at moderate efficiency under conditions compatible with in vitro transcription.

Some of the transcripts synthesized in vitro by RNA polymerase II are processed

To determine whether we could transcribe and process a histone pre-mRNA in vitro , we constructed the HLST gene, which contains the adenovirus major late promoter, a portion of the histone H2a-614 coding region, 3' end and a 140 nt region necessary for transcription termination (Fig. 2 A). A processed histone mRNA produced from this gene would be 155 nt long, and an RNA terminated at the site where transcription termination was mapped in vivo would be ~320 nt long. The sequence of the terminator region and the antisense oligonucleotides used to map the transcripts are also shown in Figure 2 A. The HLST gene was used as a template in the in vitro reactions either as a linear template ending 382 nt (Fig. 2 B) from the transcription start site, or as a supercoiled template (Figs 3 - 4 ).


Figure 3 . Termination of transcription in the nuclear extract. ( A ) The supercoiled HLST template was incubated in a nuclear extract prepared under transcription conditions. Two different extracts (I and II) are shown in lanes 2 and 3. The products were resolved by electrophoresis and detected by autoradiography. The bands labeled T are in the region expected for terminated transcripts. Lane 1 is pUC18 digested with Hpa II. ( B ) The supercoiled HLST template was incubated in the nuclear extract in the presence of antisense oligonucleotides A (lane 2), E (lane 3) or F (lane 4). The location of these oligonucleotides is shown below and in Figure 2A. The position of the DNA markers is indicated.


Figure 4 . Release of the terminated transcripts from the template. The supercoiled HLST template was incubated in a nuclear extract for 30 min. The reaction was stopped by the addition of 5 mM EDTA and immediately applied to a Biogel A15M column equilibrated with 0.5 M NaCl, 1 mM EDTA, 10 mM HEPES, pH 7.5. The RNA was purified from each reaction and analyzed by gel electrophoresis. An aliquot of each fraction was analyzed on an agarose gel to determine the position of elution of the template which was present in lanes 1-3. Lane M is pUC18 digested with Hpa II. The positions of the terminated transcripts (T) and the processed transcripts (SL -5 ) are indicated.

When the gene was linearized at a site 382 nt from the transcription start site and incubated in either the transcription extract (Fig. 2 B, lane 1) or in the mixed transcription and processing extract (Fig. 2 B, lane 2), several products accumulated. There was a major run-off product (labeled RO), and several distinct smaller products formed, including two (labeled T) which migrated in the region expected for termination products. In addition, there was a clear band at about the size expected for RNAs processed at the histone 3' end (SL -5 ) in the presence of Mg 2+ (Fig. 2 B). Synthesis of all of the RNAs was inhibited by 2 [mu]g/ml [alpha]-amanitin demonstrating that they were synthesized by RNA polymerase II (data not shown). We precisely mapped the SL -5 transcript using antisense oligonucleotides (Fig. 2 C). When the transcription and processing extracts were mixed, there was a reduction in the transcription activity but an increase in the amount of the processed RNA formed (Fig. 2 B, compare lane 2 with lane 1), consistent with the better processing efficiency of these extracts. It is difficult to estimate the processing efficiency in these reactions since many of the products are heterogeneous, but the efficiency was certainly not higher on the transcripts formed in vitro , even taking into account that the uniformly labeled run-off transcript contains about three times more radioactivity per mole than the 155 nt processed RNA. Thus there is no indication that transcripts synthesized in the extract by RNA polymerase II were processed any better than synthetic RNAs which were added to the extract.

Several experiments demonstrated that the SL -5 product ended at the end of the stem-loop and was formed by the histone mRNA processing reaction. Short transcripts can also result from the RNA polymerase stalling during transcription, often at sites of potential secondary structure in the template or RNA product. To demonstrate that some of the SL -5 product was formed by histone 3' processing, we used inhibitors of the two trans -acting factors involved in histone pre-mRNA processing, the hairpin binding factor (HBF, which binds to the stem-loop) and U7 snRNP (which base-pairs with the downstream cleavage site). Formation of the SL -5 product was partially inhibited by addition of a 30 nt RNA containing the wild-type stem-loop sequence (Fig. 2 B, lane 6). This RNA binds to the hairpin binding factor and reduces histone mRNA processing by ~90% in these extracts ( 28 ). The formation of the other transcripts was not affected by this competitor RNA, consistent with it having a specific effect of RNA processing. Formation of the SL -5 product was not blocked by a 30 nt RNA with the stem sequence reversed (Fig. 2 , lane 7), and this RNA does not bind the hairpin factor or block processing ( 28 ).

The histone 3' processing reaction is absolutely dependent on U7 snRNP and antisense oligonucleotides to the 5' end of U7 snRNP completely abolish processing (Fig. 1 C). Formation of the SL -5 transcript was partially inhibited by an antisense oligonucleotide to the 5' end of U7 snRNA (Fig. 2 C, compare lanes 1 and 4), while the overall level of transcription was not affected. Thus some of the SL -5 transcripts were formed by processing (50-80% in different experiments) and some were presumably formed by exonuclease activity, particularly in cases where the transcripts were first cleaved by RNase H, as in Figure 2 C. It is also possible that some of the SL -5 product was a result of RNA polymerase II stalling at the stem-loop. However, the production of >50% of the SL -5 product was dependent on both the hairpin binding factor and the U7 snRNP, and hence was formed by the histone mRNA processing reaction.

To map the 3' end of the SL -5 transcript, we used antisense oligonucleotides. Previously we have shown that inclusion of antisense nucleotides in the transcription reaction results in cleavage of the in vitro transcripts by RNase H and accumulation of a single product from all transcripts which extended beyond the position where the antisense oligonucleotide hybridized to the RNA transcript ( 29 ). Thus inclusion of oligonucleotide A (shown in Fig. 2 A) in the reaction resulted in conversion of all transcripts longer than 255 nt to a single 255 nt RNA (Fig. 2 C, lane 1). In addition the SL -5 product accumulated in the reaction. To map these transcripts, we used two antisense oligonucleotides. Oligonucleotide B extended to the histone pre-mRNA cleavage site 5 nt from the end of the stem-loop and oligonucleotide C extended to the base of the stem (Fig. 2 C). Inclusion of oligonucleotide B in the reaction resulted in accumulation of two major transcripts, one ending at the histone processing site and one ending at the base of the stem (Fig. 2 C, lane 2). The latter transcript was probably formed by the same activity in the extract which trims the processed histone mRNA. Inclusion of oligonucleotide C resulted in formation of a major product which has the same mobility as the processed product formed in the extract (Fig. 2 C, lane 3), demonstrating that the SL -5 product is the product which accumulates in the extract.

Further indication that histone pre-mRNA processing occurs in the extract was provided by examining the products formed after various times of incubation. In this experiment a template linearized 682 nt from the transcription start site was used. After incubation for 10 min, there were run-off transcripts formed and a transcript mapping to the histone pre-mRNA processing site, 5 nt past the end of the stem-loop (Fig. 2 D, lane 2, band SL). After incubation for 30 or 60 min there was an increase in the overall amount of transcription and in the amount of processed product. However, after incubation for 30 or 60 min all the `processed' product was the SL -5 product (Fig. 2 D, lanes 3 and 4). These results are consistent with accurate processing of the histone pre-mRNA transcripts synthesized in vitro , followed by trimming by a Mg 2+ dependent nuclease in the extract to give the SL -5 product.

Some of the transcripts are terminated at the histone termination site

We consistently noted the appearance of transcripts which migrated in the position expected for transcripts which might have been formed by transcription termination (Fig. 2 B, bands labeled T). Alternatively these and any other shorter transcripts could result from the RNA polymerase stalling at defined sites on the template. One requirement for a transcript formed by termination of transcription is that the transcript be released from the template. To determine whether any of the discrete products observed might be a result of transcription termination, we used supercoiled templates to facilitate the analysis, since the template can be readily separated from the RNA products.

When a supercoiled template containing the HLST gene was incubated with the transcription extract, there were several discrete products formed that migrated between 350 and 450 nt (based on DNA markers) as well as large heterogeneous transcripts resulting from transcription for various distances along the supercoiled template. These products were found in different extracts tested (Fig. 3 A, lanes 1 and 2) and were also present in transcripts from the linear templates (Fig. 2 B). To map the position of these transcripts we used the antisense oligonucleotides A, E and F shown in Figure 2 A. Oligonucleotide A is located 5' to the in vivo transcription termination site, oligonucleotide E is located right at the termination site and oligonucleotide F is located 30 nt 3' of the termination site. In the transcription reaction with the supercoiled template and no added oligonucleotide, there were transcripts which were the size expected for transcripts extending to near the termination site (Fig. 3 B, lane 1). Inclusion of oligonucleotide A resulted in cleavage of all of these transcripts (and the longer heterogeneous transcripts) producing the expected 255 nt RNA (Fig. 3 B, lane 2). Thus all of these transcripts were initiated from the adenovirus major late promoter. Inclusion of oligonucleotide E resulted in cleavage of the transcripts yielding a product which was almost identical in mobility to the major product observed (labeled T, Fig. 3 B, lane 3). Inclusion of oligonucleotide F, which was located at the 3' end of the terminator sequence, had no effect on the transcripts labeled T, but cleaved all the larger heterogeneous transcripts resulting in the expected 329 nt product, which were slightly larger than the products labeled T (Fig. 3 B, lane 4). From the intensity of the two products after cleavage in the presence of oligonucleotide F, we estimate that 20-30% of the transcripts end at or near the termination site. Note that since the transcripts are uniformly labeled, there is much more radioactivity in the long heterogeneous transcripts (Fig. 3 A) than in the terminated transcripts. However, when these long transcripts are cleaved the 3' fragment is probably rapidly degraded, since uncapped RNAs are rapidly degraded by a 5' -> 3' exonuclease which is Mg 2+ and ATP-dependent ( 37 ). The transcripts resulting from cleavage by RNase H and the terminated transcripts contain about the same amount of radioactivity per molecule. Thus RNAs were formed in the reaction which were initiated at the major late promoter and which ended near the expected termination site.

The terminated transcripts are released from the template

The presence of defined RNA products from the in vitro transcription reaction could result from processing of the transcripts, termination and release of the transcripts or stalling of the RNA polymerase at defined sites on the template. RNA polymerase II may stall during transcription and then resume elongation after action of an elongation factor such as TFIIS ( 38 - 43 ). TFIIS together with RNA polymerase II removes a few nucleotides to allow RNA polymerase to restart transcription at the pause site ( 44 - 46 ). A characteristic of a stalled polymerase is that both the polymerase and the RNA product remain associated with the DNA template. In contrast, terminated transcripts will be released from the template. Since transcription termination occurs at specific sequences in the DNA template, we expect most of the RNA transcripts product to remain associated with the supercoiled templates unless there is a defined termination site present in the template.

Therefore, to determine whether the RNA products were released from the template, the reaction was stopped by addition of EDTA, and then immediately applied to a Biogel A15M column separating the template from the rest of the reaction. This entire fractionation took less than 10 min. RNA was extracted from each of the fractions and analyzed by gel electrophoresis. Ten percent of each fraction was analyzed by agarose gel electrophoresis to locate the DNA template. RNA was prepared from the remaining 90% of each fraction and analyzed by electrophoresis. Most of the RNA products eluted from the column with the DNA template (Fig. 4 , lanes 2 and 3). These included a large number of products smaller than the expected termination product, indicating that these small transcripts were the result of stalled polymerases which were still associated with the template (Fig. 4 , lanes 2 and 3). The major RNAs which were not associated with the template were the RNAs which ended near the in vivo termination site. These were included in the column and eluted in a broad peak (Fig. 4 , lanes 5-10). We estimate that ~50% of the RNAs ending in the termination region were released from the template. Since termination may be at least a two-step process, involving first pausing of the RNA polymerase followed by release of the transcripts and the polymerase, there must be some paused transcripts which have not been released. The released transcripts are present presumably as heterogeneous ribonucleoprotein particles accounting for their broad distribution in the column. There was a small amount of the processed SL -5 product formed in this reaction and this was also released from the template as expected (Fig. 4 , lanes 6-9). Thus, in addition to the processed product, an RNA product which ended at or near the transcription termination site was released from the template, suggesting that proper transcription termination occurred by some of the Pol II in vitro .

Termination requires a histone 3 ' processing signal

A feature of transcription termination of transcripts from genes encoding mRNAs is that the termination can only occur after transcription past a functional 3' processing site ( 2 , 4 , 6 ). This is true for both polyadenylated mRNAs and histone mRNAs ( 24 ). To determine whether the same requirement exists in this in vitro system, we tested the effect of both removal of the 3' processing signal and mutation of the terminator sequence on formation of the terminated transcripts. Two mutations were made in the terminator region, one, HLST M1 , which deletes a portion of the terminator but does not have a significant effect on termination in cultured cells and the other, HLST M2 , which alters 9 nt and abolishes termination (our unpublished results). All four genes were transcribed in the same extract, a combination of the processing and transcription extracts. A portion of the transcription reaction containing the HLST gene was treated with the antisense oligonucleotide A which cleaves the transcripts just prior to the termination site (Fig. 5 , lane 1). There were a series of transcripts in the termination region formed from the HLST template and from the HLST M1 template which has a histone processing signal and an active terminator (Fig. 5 , lanes 2 and 4). Only large transcripts were formed from the HLT gene which lacks the histone processing site (Fig. 5 , lane 3). Since this gene has a deletion, the terminated transcripts would have been ~200 nt long. A similar result was seen with the HLST M2 template which lacks a functional terminator (Fig. 5 , lane 5). There were some processed transcripts formed from this template but there were no transcripts in the region of the terminator; instead all the transcripts extended well past the termination region (Fig. 5 , lane 5). Thus in the in vitro system, formation of the transcripts in the termination region requires both a functional 3' processing signal and an active terminator region.


Figure 5 . Termination is dependent upon the presence of a functional terminator and a histone 3' processing signal. Supercoiled templates containing the HLST gene (lanes 1 and 2), the HLT gene (lane 3), the HLST M1 gene (lane 4) and the HLST M2 gene (lane 5) were incubated in a mixture of the two nuclear extracts for 30 min. Antisense oligonucleotide A was added to the reaction in lane 1 to cleave the transcripts and provide a marker. The region labeled T(HLST) indicates the termination region of the HLST, HLST M1 and HLST M2 genes. The expected termination region for the HLT is indicated by brackets. Since the HLT gene has a deletion of the histone processing signal, the terminator has been moved 92 nt closer to the start of transcription. The RNA product was analyzed by gel electrophoresis and detected by autoradiography. The position of the marker DNAs (pUC18) digested with Hpa II is indicated.

DISCUSSION

Although in vitro systems have been developed to allow study of many of the individual reactions in mRNA biosynthesis, there are few examples of preparations which carry out multiple reactions in mRNA biosynthesis. The optimal conditions for in vitro transcription and splicing are quite different, as are the conditions for splicing and polyadenylation ( 47 ). This has made it difficult to develop a single system capable of carrying out multiple reactions in mRNA biosynthesis. Yet in the cell many of these reactions are clearly coupled, particularly splicing and polyadenylation ( 48 - 50 ) and by adjusting conditions appropriately coupling has been demonstrated in vitro ( 47 , 51 ). In the case of histone pre-mRNA only a single cleavage reaction is required to form the histone mRNA and this cleavage could function to release the nascent transcript from the template.

A second problem is that different experimental protocols are optimal for preparation of extracts active in processing and extracts active in transcription. A higher salt concentration is required to extract essential components for transcription, than to extract the essential processing components. In addition, there is an inhibitor of histone pre-mRNA processing released from nuclei at higher salt. It is likely that this is a non-specific nucleic acid binding activity, since histone pre-mRNA processing is stimulated by the addition of yeast tRNA to the extract. In vitro , histone pre-mRNA processing occurs most efficiently in the presence of high concentrations of EDTA. In reactions containing Mg 2+ it is difficult to demonstrate histone pre-mRNA processing since there are nucleases present which give products very similar to the mature histone mRNA. An ATP-dependent 3' -> 5' exonuclease has been described in mammalian nuclear extracts ( 34 ) and it is possible that this activity is responsible for some of the U7-independent formation of histone mRNA in the presence of Mg 2+ . The secondary structure of the histone mRNA or the protein-RNA complex at the 3' end of histone mRNA may block the nucleases in vitro , resulting in accumulation of histone mRNA-sized molecules. However, by determining that the formation of the processed transcripts is dependent on U7 snRNP, the transcripts formed by nuclease activity can be distinguished from the processed transcripts.

Even under conditions in which we obtained processing of the histone transcripts initiated in vitro , the efficiency of processing was not any higher on the transcripts initiated in vitro than on synthetic transcripts which were added to the reaction. Therefore in this in vitro system, we found no evidence for preferential coupling of 3' end formation to transcription in this in vitro system. Similarly in two studies where polyadenylation of transcripts initiated in vitro was reported there was not preferential processing of these transcripts ( 52 , 53 ). Thus, although in vivo it is very likely that the cleavage event leading to mRNA 3' end formation occurs on transcripts still bound to the DNA template and serves to release the transcripts from the template, these in vitro studies show no evidence of preferential coupling of cleavage of template bound transcripts compared with synthetic transcripts.

There have been only a few studies of transcription termination in vitro by Pol II using natural termination sites ( 52 , 54 - 56 ). Hyman and Moore have shown that in a yeast cell-free system, Pol II either terminates or pauses at termination sites mapped in vivo ( 57 ). Sites of RNA polymerase II termination have also been mapped using purified enzymes initiated on tailed templates ( 58 ). Whether these sites represent sites at which the enzyme terminates in vivo is not clear. Even in these studies, it was not shown that the terminated transcripts are released from the DNA template so that termination and pausing could not be distinguished.

Our results also suggest that the mechanism of transcription termination in histone genes may be distinctly different from termination in a gene encoding polyadenylated mRNA. In the proposed model for termination on a gene encoding a polyadenylated RNA, the transcription complex stalls at a site downstream from the 3' end processing signal, and the cleavage at the polyA site causes the release of the nascent transcripts from the DNA template. The RNA polymerase is released from the template after the associated uncapped RNA fragment is degraded ( 1 ). Definitive evidence that cleavage must occur prior to termination has not been obtained, and the results of one study could be interpreted to suggest that termination does not require cleavage ( 3 ). After transcription of histone genes, however, some of the intact terminated transcripts are released from the DNA template both in vivo ( 24 ) and in vitro indicating that a more complex event occurs at the termination site besides simple stalling. In vitro there is a dependence on the histone processing signal and the termination sequence, consistent with the possibility that the results observed in vitro are similar to the steps occurring in vivo . This system may provide a starting point for characterizing the factors required for termination.

ACKNOWLEDGEMENTS

We thank Zbigniew Dominski and Mike Whitfield for some of the processing extracts used in this study. This work was supported by grant GM29832 to W.F.M.

REFERENCES

1 Proudfoot,N.J. (1989) Trends Biochem. Sci. 14, 105-110. MEDLINE Abstract

2 Whitelaw,E. and Proudfoot,N. (1986) EMBO J. 5, 2915-2922. MEDLINE Abstract

3 Batt,D.B., Luo,Y. and Carmichael,G.G. (1994) Nucleic Acids Res. 22, 2811-2816. MEDLINE Abstract

4 Connelly,S. and Manley,J. (1988) Genes Dev. 2, 440-452. MEDLINE Abstract

5 Edwalds-Gilbert,G., Prescott,J. and Falck-Pedersen,E. (1993) Mol. Cell. Biol. 13, 3472-3480.

6 Logan,J., Falck-Pedersen,E., Darnell,J.E. and Shenk,T. (1987) Proc. Natl. Acad. Sci. USA 84, 8306-8310. MEDLINE Abstract

7 Ashfield,R., Enriquez Harris,P. and Proudfoot,N.J. (1991) EMBO J. 10, 4197-4207. MEDLINE Abstract

8 Pribyl,T.M. and Martinson,H.G. (1988) Mol. Cell. Biol. 8, 5369-5377. MEDLINE Abstract

9 Ashfield,R., Patel,A.J., Bossone,S.A., Brown,H., Campbell,R.D., Marcu,K.B. and Proudfoot,N.J. (1994) EMBO J. 13, 5656-5667. MEDLINE Abstract

10 Bossone,S.A., Asselin,C., Patel,A.J. and Marcu,K.B. (1992) Proc. Natl. Acad. Sci. USA 89, 7452-7456. MEDLINE Abstract

11 Roberts,S., Purton,T. and Bentley,D.L. (1992) Genes Dev. 6, 1562-1574. MEDLINE Abstract

12 Connelly,S. and Manley,J.L. (1989) Cell 57, 561-571. MEDLINE Abstract

13 Hagenbuchle,O., Wellauer,P.K., Cribbs,D.L. and Schibler,U. (1984) Cell 38, 737-744. MEDLINE Abstract

14 Citron,B., Falck-Pedersen,E., Salditt-Georgieff,M. and Darnell,J.E. (1984) Nucleic Acids Res. 12, 8723-8731. MEDLINE Abstract

15 Eggermont,J. and Proudfoot,N.J. (1993) EMBO J. 12, 2539-2548. MEDLINE Abstract

16 Enriquez-Harris,P., Levitt,N., Briggs,D. and Proudfoot,N.J. (1991) EMBO J. 10, 1833-1842.

17 Marzluff,W.F. (1992) Gene Exp. 2, 93-97. MEDLINE Abstract

18 Cotten,M., Gick,O., Vasserot,A., Schaffner,G. and Birnstiel,M.L. (1988) EMBO J. 7, 801-808. MEDLINE Abstract

19 Soldati,D. and Schümperli,D. (1988) Mol. Cell. Biol. 8, 1518-1524. MEDLINE Abstract

20 Mowry,K.L. and Steitz,J.A. (1987) Mol. Cell. Biol. 7, 1663-1672. MEDLINE Abstract

21 Mowry,K.L., Oh,R. and Steitz,J.A. (1989) Mol. Cell. Biol. 9, 3105-3108. MEDLINE Abstract

22 Gick,O., Krämer,A., Keller,W. and Birnstiel,M.L. (1986) EMBO J. 5, 1319-1326. MEDLINE Abstract

23 Chodchoy,N., Levine,B.J., Sprecher,C., Skoultchi,A.I. and Marzluff,W.F. (1987) Mol. Cell. Biol. 7, 1039-1047. MEDLINE Abstract

24 Chodchoy,N., Pandey,N.B. and Marzluff,W.F. (1991) Mol. Cell. Biol. 11, 497-509. MEDLINE Abstract

25 Vasserot,A.P., Schaufele,F.J. and Birnstiel,M.L. (1989) Proc. Natl. Acad. Sci. USA 86, 4345-4349. MEDLINE Abstract

26 Melin,L., Soldati,D., Mital,R., Streit,A. and Schümperli,D. (1992) EMBO J. 11, 691-697. MEDLINE Abstract

27 Shapiro,D., Sharp,P.A., Wahli,W. and Keller,M. (1988) DNA 7, 47-55. MEDLINE Abstract

28 Dominski,Z., Sumerel,J., Hanson,R.J. and Marzluff,W.F. (1995) RNA 1, 915-923. MEDLINE Abstract

29 Gu,X.H. and Marzluff,W.F. (1995) Nucleic Acids Res. 23, 4734-4735. MEDLINE Abstract

30 Stauber,C., Soldati,D., Lüscher,B. and Schümperli,D. (1990) Methods Enzymol. 181, 74-88. MEDLINE Abstract

31 Peltz,S.W., Brewer,G., Kobs,G. and Ross,J. (1987) J. Biol. Chem. 262, 9382-9388. MEDLINE Abstract

32 Peltz,S.W., Brewer,G., Groppi,V. and Ross,J. (1989) Mol. Biol. Med. 6, 227-238. MEDLINE Abstract

33 Ross,J., Kobs,G., Brewer,G. and Peltz,S.W. (1987) J. Biol. Chem. 262, 9374-9381. MEDLINE Abstract

34 Dominski,Z., Ferree,P. and Kole,R. (1996) Antisense Nucleic Acid Drug Dev., 6, 37-45. MEDLINE Abstract

35 Ryner,L.C., Takagaki,Y. and Manley,J.L. (1989) Mol. Cell. Biol. 9, 4229-4238. MEDLINE Abstract

36 Cotten,M., Oberhauser,B., Brunar,H., Holzner,A., Issakides,G., Noe,C.R., Schaffner,G., Wagner,E. and Birnstiel,M.L. (1991) Nucleic Acids Res. 19, 2629-2635. MEDLINE Abstract

37 Murthy,K.G.K., Park,P. and Manley,J.L. (1991) Nucleic Acids Res. 19, 2685-2692. MEDLINE Abstract

38 Bengal,E., Flores,O., Krauskopf,A., Reinberg,D. and Aloni,Y. (1991) Mol. Cell. Biol. 11, 1195-1206. MEDLINE Abstract

39 Wang,D. and Hawley,D.K. (1993) Proc. Natl. Acad. Sci. USA 90, 843-847. MEDLINE Abstract

40 Bradsher,J.N., Tan,S., McLaury,H.-J., Conaway,J.W. and Conaway,R.C. (1993) J. Biol. Chem. 268, 25594-25603. MEDLINE Abstract

41 Christie,K.R., Awrey,D.E., Edwards,A.M. and Kane,C.M. (1994) J. Biol. Chem. 269, 936-943. MEDLINE Abstract

42 Gu,W. and Reines,D. (1995) J. Biol. Chem. 270, 11238-11244. MEDLINE Abstract

43 SivaRaman,L., Reines,D. and Kane,C.M. (1990) J. Biol. Chem. 265, 14554-14560. MEDLINE Abstract

44 Izban,M.G. and Luse,D.S. (1992) J. Biol. Chem. 267, 13647-13655. MEDLINE Abstract

45 Izban,M.G. and Luse,D.S. (1992) Genes Dev. 6, 1342-1356. MEDLINE Abstract

46 Rudd,M.D., Izban,M.G. and Luse,D.S. (1994) Proc. Natl. Acad. Sci. USA 91, 8057-8061. MEDLINE Abstract

47 Niwa,M., Rose,S.D. and Berget,S.M. (1990) Genes Dev. 4, 1552-1559. MEDLINE Abstract

48 Pandey,N.B., Chodchoy,N., Liu,T.-J. and Marzluff,W.F. (1990) Nucleic Acids Res. 18, 3161-3170. MEDLINE Abstract

49 Nesic,D. and Maquat,L.E. (1994) Genes Dev. 8, 363-375. MEDLINE Abstract

50 Nesic,D., Zhang,J. and Maquat,L.E. (1995) Mol. Cell. Biol. 15, 488-496. MEDLINE Abstract

51 Niwa,M. and Berget,S.M. (1991) Genes Dev. 5, 2086-2095. MEDLINE Abstract

52 Miralles,V.J. (1991) Nucleic Acids Res. 19, 3593-3599. MEDLINE Abstract

53 Mifflin,R.C. and Kellems,R.E. (1991) J. Biol. Chem. 266, 19593-19598. MEDLINE Abstract

54 Wiest,D.K. and Hawley,D.K. (1990) Mol. Cell. Biol. 10, 5782-5795. MEDLINE Abstract

55 Wilson-Gunn,S.I., Kilpatrick,J.E. and Imperiale,M.J. (1992) J. Virol. 66, 5418-5424.

56 Ueno,A., Baek,K., Jeon,C. and Agarwal,K. (1992) Proc. Natl. Acad. Sci. USA 89, 3676-3680. MEDLINE Abstract

57 Hyman,L.E. and Moore,C.L. (1993) Mol. Cell. Biol. 13, 5159-5167. MEDLINE Abstract

58 Kerppola,T.K. and Kane,C.M. (1990) Biochemistry 29, 269-278. MEDLINE Abstract


Return

* To whom correspondence should be addressed
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Genes Dev.Home page
P. Richard and J. L. Manley
Transcription termination by nuclear RNA polymerases
Genes & Dev., June 1, 2009; 23(11): 1247 - 1269.
[Abstract] [Full Text] [PDF]


Home page
RNAHome page
A. Nag, K. Narsinh, A. Kazerouninia, and H. G. Martinson
The conserved AAUAAA hexamer of the poly(A) signal can act alone to trigger a stable decrease in RNA polymerase II transcription velocity
RNA, August 1, 2006; 12(8): 1534 - 1544.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
N. J. Park, D. C. Tsao, and H. G. Martinson
The Two Steps of Poly(A)-Dependent Termination, Pausing and Release, Can Be Uncoupled by Truncation of the RNA Polymerase II Carboxyl-Terminal Repeat Domain
Mol. Cell. Biol., May 15, 2004; 24(10): 4092 - 4103.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. J. Kim and H. G. Martinson
Poly(A)-dependent Transcription Termination: CONTINUED COMMUNICATION OF THE POLY(A) SIGNAL WITH THE POLYMERASE IS REQUIRED LONG AFTER EXTRUSION IN VIVO
J. Biol. Chem., October 24, 2003; 278(43): 41691 - 41701.
[Abstract] [Full Text] [PDF]


Home page
Microbiol. Mol. Biol. Rev.Home page
J. Zhao, L. Hyman, and C. Moore
Formation of mRNA 3' Ends in Eukaryotes: Mechanism, Regulation, and Interrelationships with Other Steps in mRNA Synthesis
Microbiol. Mol. Biol. Rev., June 1, 1999; 63(2): 405 - 445.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Print PDF (237K) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Gu, X
Right arrow Articles by Marzluff, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gu, X
Right arrow Articles by Marzluff, W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?